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Introduction {#sec001}
============

The cytochrome P450 superfamily consists of many heme-containing monooxygenases. They are best known for their roles in drug metabolism. CYP1B1 is involved in many processes in the body, such as assisting with reactions that break down drugs and produce certain fats (lipids). It is expressed in both adult and fetal human extrahepatic tissues, including most of the parenchymal and stromal tissues from brain, kidney, prostate, breast, cervix, uterus, ovary, lymph nodes \[[@pone.0231752.ref001]\], and ocular tissues \[[@pone.0231752.ref002], [@pone.0231752.ref003]\]. Mutations in this enzyme are a risk factor for the development of primary congenital glaucoma in humans \[[@pone.0231752.ref004]\]. However, the underlying cellular and molecular mechanisms are not fully revealed.

We previously showed expression of Cyp1b1 is essential for ischemia-mediated retinal neovascularization as occurs in retinopathy of prematurity, and the proangiogenic function of retinal vascular cells in culture \[[@pone.0231752.ref005]--[@pone.0231752.ref007]\]. However, how Cyp1b1 expression impacts these processes remained largely unknown. We showed Cyp1b1 is constitutively expressed in vascular endothelial cells and perivascular supporting cells from vascular beds of many organs including retina \[[@pone.0231752.ref005], [@pone.0231752.ref007]\]. Recently, we also demonstrated that Cyp1b1 is expressed in retinal astrocytes (AC), and *Cyp1b1*-/- retinal AC are more proliferative and migratory \[[@pone.0231752.ref008]\]. These cells produced increased amounts of fibronectin and its receptors αvβ3 and α5β1 integrins. However, production of inflammatory mediators such as BMP-7 and MCP-1 were decreased in *Cyp1b1*-/- AC. In addition, we observed a significant increase in CD38 expression when *Cyp1b1*-/- AC were challenged with H~2~O~2~ compared with *Cyp1b1*+/+ cells. *Cyp1b1*-/- AC also showed enhanced connexin 43 phosphorylation compared with *Cyp1b1*+/+ cells \[[@pone.0231752.ref008]\]. Thus, Cyp1b1-deficiency in AC was associated with increased resistance towards oxidative stress.

Astrocytes are the major cell type in the optic nerve head and are vital to the development and maintenance of the retinal astrocytic network and angiogenesis \[[@pone.0231752.ref009], [@pone.0231752.ref010]\]. Under pathological conditions, AC become reactive and contribute to various ocular pathologies including glaucoma and diabetic retinopathy \[[@pone.0231752.ref011]\]. However, there still much more to delineate regarding Cyp1b1 expression and function in AC. The few studies available to date have confirmed Cyp1b1 expression in AC and neurons, and its upregulation in a variety of gliomas \[[@pone.0231752.ref001], [@pone.0231752.ref012]\]. To our knowledge, we were first to report the impact of Cyp1b1 expression on retinal AC function. However, the intracellular pathways that mediate these activities of Cyp1b1 in AC remain elusive.

RNAseq is one transcriptomic approach where the total complement of RNAs from a given sample is isolated and sequenced using high-throughput technologies \[[@pone.0231752.ref013]\]. RNAseq technology has the potential to provide very useful, detailed information on the intracellular pathways impacted by Cyp1b1 expression, and identify the networks of genes involved. The purpose of the current study was to utilize this powerful technique to delineate the detailed molecular mechanisms of Cyp1b1 action in retinal AC by determining the changes in patterns of gene expression networks impacted by Cyp1b1 expression. The identification of genes whose expression is affected by the presence or absence of Cyp1b1 will provide additional clues to the intracellular mechanisms of Cyp1b1 action and function in retinal AC. This knowledge should lead to the discovery of new targets for modulation of Cyp1b1 activity and their potential therapeutic use.

Results {#sec002}
=======

RNAseq analysis and global gene expression profiles of *Cyp1b1+*/+ and *Cyp1b1-*/- retinal AC {#sec003}
---------------------------------------------------------------------------------------------

In order to investigate the impact of Cyp1b1 expression on the transcriptome profile of retinal AC, we performed RNAseq analysis of *Cyp1b1*+/+ and *Cyp1b1*-/- AC. All samples were uniquely barcoded, pooled and sequenced in one lane on an Illumina HiSeq 2500 platform. The average number of reads for *Cyp1b1*+/+ AC was 2.34x10^7^ and for *Cyp1b1*-/- AC was 2.32x10^7^. All sequence reads were mapped to the reference mouse genome using STAR (Spliced Transcripts Alignment to a Reference) \[[@pone.0231752.ref014]\]. To determine the expression level of various genes, mapped paired-end reads for genes were counted in each sample using RSEM (RNASeq by Expectation Maximization) \[[@pone.0231752.ref015]\]. Gene expression was normalized by the method of trimmed mean of M-values (TMM), where the product of this factor and the library sizes defines the effective library size \[[@pone.0231752.ref016]\]. For each sample contrast, simple boxplots per sample expression distributions were constructed before and after TMM normalization ([Fig 1A](#pone.0231752.g001){ref-type="fig"}). Overall TMM values were similar in each sample, indicated by the uniform distributions.

![Gene expression profiles of the *Cyp1b1*+/+ and *Cyp1b1*-/- retinal AC.\
(A) Box plot showing overall TMM expression values for the *Cyp1b1*-/- AC and control samples. (B) Volcano plot showing differentially express genes. For each plot, the X-axis represents log~2~ FC and the Y-axis represents -log~10~ (FDR). The differentially expressed genes (DEG) are shown as red indicating increased expression and blue indicating decreased expression. (C) Hierarchical clustering of DEG. Red indicates increased expression and green indicates decreased expression. The DEG were defined as having absolute FC\> 1.5 and an FDR\< 0.05.](pone.0231752.g001){#pone.0231752.g001}

Analysis of differentially expressed genes was performed with a glm using the edgeR package \[[@pone.0231752.ref017]\]. In order to decide which genes are differentially expressed (DEG), the adjusted p-value-not the raw p-value- was defined to be 0.05. To control the false discovery rate (FDR), a Benjamini-Hochberg correction was applied \[[@pone.0231752.ref018]\]. [Fig 1B](#pone.0231752.g001){ref-type="fig"} represents a Volcano plot showing DEG as red and blue dots denoting up- and down-regulated expression, respectively, at an adjusted p-value (FDR) significance threshold of 0.05. The gray dots reflect those genes with no evidence of statistically significant changes in expression. The two solid gray lines denote the boundary of a two-fold change. We also conducted a hierarchical clustering analysis of DEG from all samples with Ward's method of Euclidean distances \[[@pone.0231752.ref019]\], and created a heatmap with the heatmap function from Heatmapper: web-enabled heat mapping for all \[[@pone.0231752.ref020]\]. The results indicated that gene expression was similar in each group ([Fig 1C](#pone.0231752.g001){ref-type="fig"}).

The samples from the *Cyp1b1*+/+ and *Cyp1b1*-/- AC groups were assayed for DEG. The threshold was adjusted to Log2 fold-change with an absolute value of 2.0 and a p-value \<1e-7. This yielded 585 transcripts (236 up- and 349-downregulated) for the downstream pathway analysis. The 20 most up- and downregulated genes are listed in [Table 1](#pone.0231752.t001){ref-type="table"}. Within the top upregulated genes, we identified the following genes: Dsp (6.81-fold), Uty (11.92-fold), Cysltr1 (8.34-fold), Cdx2 (6.47-fold) and Kdm5d (10.28-fold). These genes have important roles in different biological and molecular processes including actin-mediated cell contraction, cardiac muscle contraction, oxidoreductase activity, and demethylase activity among others \[[@pone.0231752.ref021]--[@pone.0231752.ref024]\]. The top downregulated genes including Ptprf (-1.01-fold), Fgf10 (-1.03-fold), Prl2c3 (-1.034), Tgfb3 (-1.04-fold), Mical1 (-1.05-fold), Ndrg2 (-1.05-fold), Ptgs1 (-1.0487-fold), Aplp1 (-1.08-fold), and Steap3 (-1.08-fold) have important roles in processes including cell proliferation, apoptosis, regulation of DNA replication, and metabolic processes among others \[[@pone.0231752.ref025]--[@pone.0231752.ref027]\]. DEG (585 total) were subjected to Gene Ontology to establish a connection with the biological processes and molecular functions that these genes contribute to ([Fig 2](#pone.0231752.g002){ref-type="fig"}).

![The biological process and molecular functions significantly impacted in *Cyp1b1*-/- AC.\
(A) Bar graph of the biological process categories. (B) Bar graph of the molecular function. DEG were subjected to GO enrichment analysis having absolute FC\> 2 and a FDR\< 0.05.](pone.0231752.g002){#pone.0231752.g002}
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###### Top 20 up- and down-regulated genes in Cyp1b1-/-AC.

![](pone.0231752.t001){#pone.0231752.t001g}

  Symbol               Description                                                                       Log2FC      p-value     FDR
  -------------------- --------------------------------------------------------------------------------- ----------- ----------- -----------
  **Up-regulated**                                                                                                               
  Eif2s3y              eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked   12.01499    0           0
  Uty                  ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome              11.91885    3.6E-164    1.9E-161
  Ddx3y                DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked                                11.79096    0           0
  Kdm5d                lysine (K)-specific demethylase 5D                                                10.28087    8.9E-151    4E-148
  Gm43302              predicted gene 43302                                                              9.580986    1.21E-12    2E-11
  Rpl15-ps2            ribosomal protein L15, pseudogene 2                                               9.550535    2.2E-235    3.8E-232
  Bmp8b                bone morphogenetic protein 8b                                                     8.847732    0           0
  Cysltr1              cysteinyl leukotriene receptor 1                                                  8.342675    1.93E-30    1.16E-28
  Gm26760              predicted gene, 26760                                                             8.102196    5.58E-28    2.97E-26
  Gm10020              predicted pseudogene 10020                                                        7.874941    1.6E-233    2.5E-230
  Gm6969               predicted pseudogene 6969                                                         6.85453     7.82E-74    1.63E-71
  Dsp                  desmoplakin                                                                       6.813457    9.78E-10    1.13E-08
  Actg-ps1             actin, gamma, pseudogene 1                                                        6.722348    1.08E-11    1.58E-10
  Sgsm1                small G protein signaling modulator 1                                             6.689262    1.12E-59    1.78E-57
  Cdx2                 caudal type homeobox 2                                                            6.474141    2.61E-26    1.27E-24
  Gm38312              predicted gene, 38312                                                             6.410902    1.62E-77    3.66E-75
  Oxct2b               3-oxoacid CoA transferase 2B                                                      6.374568    4.13E-23    1.59E-21
  AI593442             expressed sequence AI593442                                                       6.040882    1.6E-116    6E-114
  Gm45315              predicted gene 45315                                                              6.018783    7.76E-65    1.3E-62
  Adarb2               adenosine deaminase, RNA-specific, B2                                             5.88212     2.23E-18    6.17E-17
  **Down-regulated**                                                                                                             
  Ptprf                protein tyrosine phosphatase, receptor type, F                                    -1.009044   3.978E-53   5.686E-51
  Gprc5a               G protein-coupled receptor, family C, group 5, member A                           -1.02267    2.718E-12   4.306E-11
  Vax2                 ventral anterior homeobox 2                                                       -1.025959   5.515E-10   6.507E-09
  Fgf10                fibroblast growth factor 10                                                       -1.028563   3.695E-21   1.264E-19
  Stard9               START domain containing 9                                                         -1.030828   2.45E-13    4.349E-12
  Lmo1                 LIM domain only 1                                                                 -1.031322   5.887E-17   1.438E-15
  Prl2c3               prolactin family 2, subfamily c, member 3                                         -1.034173   1.076E-22   4.025E-21
  Gm27177              predicted gene 27177                                                              -1.034225   3.073E-17   7.67E-16
  Tgfb3                transforming growth factor, beta 3                                                -1.035388   2.308E-12   3.687E-11
  Flrt3                fibronectin leucine rich transmembrane protein 3                                  -1.038403   8.71E-09    8.981E-08
  Acsf2                acyl-CoA synthetase family member 2                                               -1.040813   9.692E-12   1.426E-10
  Ppic                 peptidylprolyl isomerase C                                                        -1.042228   5.977E-32   3.847E-30
  Eif3j1               eukaryotic translation initiation factor 3, subunit J1                            -1.042647   4.709E-42   5.158E-40
  Mical1               microtubule associated monooxygenase, calponin and LIM domain containing 1        -1.046611   1.687E-09   1.899E-08
  Ndrg2                N-myc downstream regulated gene 2                                                 -1.047743   2.791E-13   4.941E-12
  Ptgs1                prostaglandin-endoperoxide synthase 1                                             -1.0487     5.856E-29   3.273E-27
  Cbr3                 carbonyl reductase 3                                                              -1.050294   2.114E-16   4.933E-15
  Slfn8                schlafen 8                                                                        -1.061261   4.262E-23   1.64E-21
  Aplp1                amyloid beta (A4) precursor-like protein 1                                        -1.075804   8.932E-14   1.662E-12
  Steap3               STEAP family member 3                                                             -1.08044    5.467E-14   1.046E-12

The cutoff criteria for this list was any DEG with a FC\> 5.88 for upregulation and FC\> -1.009 for downregulation.

Pathway enrichment analysis, conducted using KEGG (Kyoto Encyclopedia of Genes and Genomes) \[[@pone.0231752.ref028]--[@pone.0231752.ref030]\] as a mapping database, 57 pathways were identified with significance level of 0.05. To cut down on the list the P\< 0.002 was applied. The pathways with multiple points of commonality and overlap among the Axon guidance, extracellular matrix-receptor interactions, pathways in cancer, cell adhesion molecules, TGF-β signaling pathways, and the focal adhesion were identified as most significantly enriched pathways ([Table 2](#pone.0231752.t002){ref-type="table"}).

10.1371/journal.pone.0231752.t002

###### Pathway enrichment analysis of significantly changed genes.

![](pone.0231752.t002){#pone.0231752.t002g}

  KEGG Pathway name                         Pathway Rank   GENES                                                                                                                                                        FDR adjusted enrichment score p-value
  ----------------------------------------- -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------
  Axon guidance                             1              Sema3c, Unc5d, Sema5a, Sema3g, Ngef, Lrrc4c, Sema6b, Cxcl12, Unc5c, Sema4f, Plxnb1, Sema6a                                                                   3.32e-07
  ECM-receptor interaction                  2              Itga1, Col1a2, Lama2, Tnxb, Spp1, Lama5, Col5a3, Npnt, Thbs2                                                                                                 4.79e-06
  Pathways in cancer                        3              Dapk1, Arnt2, Wnt5b, Lama2, Pgf, Hhip, Apc2, Fgf7, Pax8, Lama5, Wnt4, Tgfb3, Ar, Mmp2, Fgf10                                                                 1.31e-05
  Cell adhesion molecules (CAMs)            4              Vcan, Cdh4, Cd80, Cldn1, Vcam1, Cd34, Ptprf, Cdh3, Icam1                                                                                                     0.0002
  TGF-beta signaling pathway                5              Tgfb3, Gdf5, Fst, Lefty1, Bmp7, Bmp8b, Thbs2                                                                                                                 0.0002
  Focal adhesion                            6              Itga1, Col1a2,Lama2,Pgf, Tnxb, Spp1, Lama5, Col5a3, Myl12b,Thbs2                                                                                             0.0002
  Neuroactive ligand-receptor interaction   7              Lepr, Adra1d, Htr1b, Gria4, Grid2, Htr2a, Cysltr1,Drd4, Calcrl, Grid1                                                                                        0.0020
  Metabolic pathways                        8              Mgat3, Itpkb, Cda, Xylb, Pla2g4b, Abat, Ckb, Ass1, Isyna1, Aldh1a7, Aldh1a1, Nnmt, Cbr2, B3gnt3, Cbr3, Gldc, Eno2, Ptgs1, Bdh2, Ldhb, Gatm, St3gal1, Sardh   0.0041
  Calcium signaling pathway                 9              Adcy7, Cacna1d, Itpkb, Cacna1h, Adra1d, Htr2a, Cysltr1                                                                                                       0.0058
  Cytokine-cytokine receptor interaction    10             Lepr, Ccl7, Bmp7, Tgfb3, Tnfsf10, Cxcl11, Cxcl12, Gdf5                                                                                                       0.0077
  MAPK signaling pathway                    11             Mapk13, Tgfb3, Cacna1d, Cacna1h, Pla2g4b, Fgf10, Fgf7                                                                                                        0.0277

**Significantly changed transcriptome**. Column 1 lists the canonical KEGG pathway name, column 2 lists the pathway enrichment score rank in terms of p-value determined by hypergeometric test, column 3 lists the genes that mapped to the KEGG pathway, and column 4 shows the FDR adjusted p-value of significance of the pathway enrichment score.

To validate the RNAseq findings, RT-qPCR were performed on newly extracted RNA from *Cyp1b1*+/+AC and *Cyp1b1*-/-AC. From each KEGG pathway, we selected key genes with important roles in angiogenesis, apoptosis, cell proliferation, cell migration, metabolism and inflammation. We selected 27 genes (Cxcl12, Cxcl11, Col1a2, Arnt2, Fgf7, Mmp2, Bmp7, Thsb2, Bmp8b, Cdh3, Cdh4, Gdf5, Cd80, Cldn1, Lefty1, Cysltr1, Drd4, Aldh1a7, Cbr2, B3gnt3, Cbr3, Ldhb, Gatm, Adcy7, Cacna1d, Ccl7, and Mapk13) involved in the pathways identified in [Table 2](#pone.0231752.t002){ref-type="table"}. We examined changes in their expression by RT-qPCR (Figs [3](#pone.0231752.g003){ref-type="fig"} and [4](#pone.0231752.g004){ref-type="fig"}). The results obtained with RT-qPCR showed similar changes in expression as those obtained from the RNAseq studies ([Table 3](#pone.0231752.t003){ref-type="table"}). However, the changes in the expression of a number of these genes did not reach significant levels. These included Cxcl12, Cysltr1, Cacna1d, Col1a2, Aldh1a7, Cbr2, B3gnt3, Gatm, and Lefty1.

![RT-qPCR validation of DEG from different pathways.\
(A) Genes related to the axon guidance pathway. (B) Genes related to the Neuroactive ligand-receptor interaction pathway. (C) Genes related to the Calcium signaling pathway. (\*\*P\<0.01, \*\*\*\*P\<0.0001, n≥ 6).](pone.0231752.g003){#pone.0231752.g003}

![RT-qPCR validation of DEG from different pathways.\
(A) Genes related to the Cancer pathway. (B) Genes related to the ECM-Receptor and Focal adhesion pathways. (C) Genes related to the Cell adhesion molecules pathways. (D) Genes related to the metabolic pathways. (E) Genes related to the Cytokine-Cytokine interaction pathways. (F) Genes related to the TGF-β signaling pathway. (G) Genes related to the MAPK signaling pathways. (\*P\<0.05, \*\*P\<0.01, \*\*\*\*P\<0.0001, n≥ 6).](pone.0231752.g004){#pone.0231752.g004}

10.1371/journal.pone.0231752.t003

###### Differentially expressed gene selected for RT-qPCR validation.

![](pone.0231752.t003){#pone.0231752.t003g}

  KEGG pathway name                              Symbol                                                               Gene Description                                   Log~2~FC    p-value
  ---------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------- ----------- -----------
  **Axon Guidance**                              Cxcl12                                                               chemokine (C-X-C motif) ligand 12                  1.10        2.39E-89
  **ECM-receptor interaction**                   Col1a2                                                               collagen, type I, alpha 2                          5.74        1.69E-15
  Thbs2                                          thrombospondin 2                                                     2.67                                               4.62E-12    
  **Pathways in cancer**                         Arnt2                                                                aryl hydrocarbon receptor nuclear translocator 2   1.70        1.28E-111
  Fgf7                                           fibroblast growth factor 7                                           1.28                                               6.02E-86    
  Mmp2                                           matrix metallopeptidase 2                                            5.28                                               1.77E-13    
  **Cell adhesion molecules**                    Cdh4                                                                 cadherin 4 (retinal)                               3.23        2.45E-153
  Cd80                                           CD80 antigen                                                         -3.52                                              7.99E-27    
  Cldn1                                          claudin 1                                                            4.64                                               4.05E-173   
  Cdh3                                           cadherin 3 (placental)                                               3.75                                               3.80E-54    
  **TGF-β signaling**                            Gdf5                                                                 growth differentiation factor 5                    4.65        2.08E-11
  Lefty1                                         left right determination factor 1                                    2.62                                               1.32E-12    
  Bmp7                                           bone morphogenetic protein 7                                         -2.31                                              2.04E-59    
  Bmp8b                                          bone morphogenetic protein 8b                                        8.85                                               0           
  Thbs2                                          thrombospondin 2                                                     2.67                                               4.62E-12    
  **Focal adhesion**                             Col1a2                                                               collagen, type I, alpha 2                          5.74        1.69E-15
  Thbs2                                          thrombospondin 2                                                     2.67                                               4.62E-12    
  **Neuroactive ligand- receptor interaction**   Cysltr1                                                              cysteinyl leukotriene receptor 1                   8.34        1.93E-30
  Drd4                                           dopamine receptor D4                                                 3.32                                               1.86E-11    
  **Metabolic pathways**                         Aldh1a7                                                              aldehyde dehydrogenase family 1, subfamily A7      3.34        1.25E-25
  Cbr2                                           carbonyl reductase 2                                                 2.20                                               3.12E-10    
  B3gnt3                                         UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3        -5.21                                                          
  Cbr3                                           carbonyl reductase 3                                                 -1.05                                              2.114E-16   
  Ldhb                                           lactate dehydrogenase B                                              2.15                                               7.57E-21    
  Gatm                                           glycine amidinotransferase (L-arginine:glycine amidinotransferase)   -4.63                                              6.11E-40    
  **Calcium signaling**                          Adcy7                                                                adenylate cyclase 7                                1.34        2.44E-15
  Cacna1d                                        calcium channel, voltage-dependent, L type, alpha 1D subunit         3.87                                               5.65E-13    
  Cysltr1                                        cysteinyl leukotriene receptor 1                                     8.34                                               1.93E-30    
  **Cytokine-cytokine receptor interaction**     Ccl7                                                                 chemokine (C-C motif) ligand 7                     -2.40       9.08E-10
  Bmp7                                           bone morphogenetic protein 7                                         -2.31                                              2.04E-59    
  Cxcl11                                         chemokine (C-X-C motif) ligand 11                                    2.96                                               2.05E-20    
  Cxcl12                                         chemokine (C-X-C motif) ligand 12                                    1.10                                               2.39E-89    
  Gdf5                                           growth differentiation factor 5                                      4.65                                               2.08E-11    
  **MAPK signaling**                             Mapk13 (P38-delta)                                                   mitogen-activated protein kinase 13                1.66        5.24E-52
  Cacna1d                                        calcium channel, voltage-dependent, L type, alpha 1D subunit         3.87                                               5.65E-13    
  Fgf7                                           fibroblast growth factor 7                                           1.28                                               6.02E-86    

The expression of selected genes related to the KEGG pathways were validated by RT-qPCR. LogFC and p-values were obtained from RNAseq analysis.

Discussion {#sec004}
==========

In this study we used RNAseq analysis to determine the global transcriptome profile of *Cyp1b1*+/+ and *Cyp1b1*-/- AC from mouse retina. We identified 585 DEG, whose pathway analysis revealed the most significant biological functions. These included the Axon guidance, extracellular matrix (ECM)-receptor interactions, pathways in cancer, cell adhesion molecules, TGF-β signaling, and the focal adhesion regulation. We also found that some of the top downregulated genes were involved in biological and molecular processes including actin-mediated cell contraction, cardiac muscle contraction, cell proliferation, apoptosis and metabolic processes.

Our findings here were consistent with the results of our previous studies showing increased proliferation and migration of *Cyp1b1-/-* AC. Activation of AC proliferation and migration is important in repair of injuries in the central nervous system (CNS) and scar formation \[[@pone.0231752.ref031], [@pone.0231752.ref032]\]. AC migration is regulated by various factors, among which transforming growth factor-β (TGF-β) plays an important role \[[@pone.0231752.ref033]\]. In AC, TGF-β suppresses cell proliferation by inducing p15^INK4B^ expression in a Smad3-dependent manner \[[@pone.0231752.ref034]\]. This is consistent with our findings that showed the downregulation of TGF-β in *Cyp1b1*-/- AC. The upregulation of Smad genes in *Cyp1b1* -/- AC was associated with the enhanced pathways in axon guidance and cell proliferation.

Our results showed changes in Cxcl12, (also known as SDF-1). Cxcl12 is one of the most studied chemokines that induce cell proliferation and migration by binding to its receptor. Under normal conditions, Cxcl12 expression in the CNS is relatively low. However, its expression is upregulated when the CNS is affected by trauma, ischemia, inflammation or infection \[[@pone.0231752.ref035]\]. Enhanced Cxcl12 expression promotes proliferation of radial glia like cells after traumatic brain injury in rats \[[@pone.0231752.ref036]\]. Others have shown its therapeutic value by promoting autophagy and migration via PI3K-AKT-mTOR pathway \[[@pone.0231752.ref037]\].

We recently showed that Cyp1b1 deficiency affects retinal AC ECM production and expression of integrin receptors \[[@pone.0231752.ref008]\]. We also showed upregulation of cadherins, laminin, and tenascin. These molecules are well known for their roles in cell adhesion \[[@pone.0231752.ref038]\], and were associated with changes in adhesion observed in *Cyp1b1*-/- retinal AC \[[@pone.0231752.ref008]\]. Cadherin-4 (also known as R-cadherin) is involved in retinal angiogenesis during development. Dorrell et al. \[[@pone.0231752.ref039]\] used antibodies or peptides to neutralize R-cadherin, which prevented the normal formation of the retinal vascular network in newborn mice. They also showed that R-cadherin plays a crucial role in the endothelial--astrocyte interactions \[[@pone.0231752.ref039], [@pone.0231752.ref040]\]. Thus, Cyp1b1 expression may impact AC interactions with EC.

Oxidative stress is implicated in many neurodegenerative diseases. Cytochrome P450 activities are generally involved in ROS production due to their involvement in the metabolism of steroids, fat-soluble vitamins, fatty acids, eicosanoids, drugs, carcinogens, and other xenobiotic chemicals \[[@pone.0231752.ref041]--[@pone.0231752.ref043]\]. CYP enzymes can generate superoxide and hydrogen peroxide through uncoupling reactions, for more details see \[[@pone.0231752.ref044]\]. We have demonstrated an important role for Cyp1b1 as a modulator of cellular redox state \[[@pone.0231752.ref045]\]. Studies utilizing vascular cells derived from *Cyp1b1*-/- mice showed an increase in oxidative stress in vascular endothelial cells and perivascular supporting cells \[[@pone.0231752.ref005], [@pone.0231752.ref007], [@pone.0231752.ref046]\]. In contrast, *Cyp1b1*-/- retinal AC did not show an increase in oxidative stress compared to *Cyp1b1*+/+ cells under basal conditions \[[@pone.0231752.ref008]\]. This is consistent with minimal changes in expression of genes that affect cellular redox state in the absence of Cyp1b1. However, incubation of these cells with known inducers of oxidative stress could reveal changes in genes that modulate oxidative stress. This notion is supported by our studies demonstrating that *Cyp1b1*-/- AC elicit a significantly more robust response in expression of CD38 when challenged with H~2~O~2~ compared with *Cyp1b1*+/+ cells \[[@pone.0231752.ref047]\]. Thus, the elucidation of the mechanisms behind AC resilience to oxidative stress, especially in the absence of Cyp1b1, needs further investigation.

Cytochrome P450 enzymes are involved in metabolism of drugs, and are major source of variability in drug pharmacokinetics and responses. However, in some cases they can also activate compounds consumed in food, converting pro-carcinogens to carcinogens \[[@pone.0231752.ref048]\]. CYP proteins, involved in steroid or retinoic acid metabolism, could promote or suppress tumors development through hormonal control \[[@pone.0231752.ref049], [@pone.0231752.ref050]\]. Genetic variability could play a role if a polymorphism affected a CYP protein involved in such processes \[[@pone.0231752.ref051]\]. Our study found multiple genes in the cancer pathway that are associates with the progression or suppression of cancer such as laminin, Tgfβ3, Hhip, Arnt2 and Mmp2 \[[@pone.0231752.ref052]--[@pone.0231752.ref054]\]. Mmp2 was upregulated in this pathway and is implicated in cancer cell migration \[[@pone.0231752.ref055]\]. A previous study using a microarray analysis, demonstrated that the increased expression of Mmp2 is involved in invasiveness of malignant glioma \[[@pone.0231752.ref056], [@pone.0231752.ref057]\], an observation that is consistent with our findings. Thus, Cyp1b1 expression has an important role in modulating AC migration by suppressing Mmp2 expression.

A limitation of our studies is the use of cells prepared from mix genders. Our initial in vivo and in vitro vascular cell culture studies did not demonstrate a gender bias in the noted phenotypes with *Cyp1b1*-deficiency. However, our gene expression studies here showed some of the differentially expressed genes in Cyp1b1 null cells are sex linked: Uty; Y-chromosome, Cysltr1; X-chromosome, and Kdm5d; Y-chromosome. Thus, Cyp1b1-deficiency impact on gene expression, and likely noted phenotypes, could be deferentially impacted by gender. Future studies will further address the gender contributions to various phenotypes noted with *Cyp1b1*-deficiecny.

In summary, RNAseq technology was used to investigate the transcriptome profiles of retinal AC and how Cyp1b1 expression modulates their cellular functions. A pathway analysis of DEG indicated the most significantly enriched pathways included Axon guidance, ECM-receptor interactions, as well as cancer and other pathways (cell proliferation, focal adhesion, and cell adhesion). Our transcriptomic approach in this investigation, which relied on RNAseq, was powerful and effective way to allow us to obtain a global view of genes whose expression are impacted by Cyp1b1, likely in a gender dependent manner.

Materials and methods {#sec005}
=====================

Ethics statement {#sec006}
----------------

All animal experiments were performed in accordance to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of the University of Wisconsin School of Medicine and Public Health (the assurance number A3368-01). Animals were sacrificed according to an approved protocol by CO2 asphyxiation.

Isolation and culture of Cyp1b1-/- retinal AC {#sec007}
---------------------------------------------

Retinal AC were isolated from mouse retina by collecting retinas from one litter of 4-week-old (6 to 7- mix gender) mice using a dissecting microscope, as previously described by us with greater than 98% purity \[[@pone.0231752.ref008], [@pone.0231752.ref058]\]. Briefly, retinas (12 to 14) were rinsed with serum-free Dulbecco's Modified Eagle's Medium (DMEM), pooled in a 60 mm dish, minced and digested for 45 min with collagenase Type I (1 mg/ml; Worthington, Lakewood, NJ) in serum-free DMEM at 37°C. Cells were rinsed in DMEM containing 10% fetal bovine serum (FBS) and centrifuged for 5 min at 400 xg. Digested cells were rinsed again in DMEM containing 10% FBS and filtered through a double layer of sterile 40 μm nylon mesh (Sefar America Inc., Fisher Scientific, Hanover Park, IL). Cells were centrifuged for 5 min at 400 xg and medium was aspirated. Cells were washed twice with DMEM containing 10% FBS, resuspended in 1 ml of DMEM containing 10% FBS in a 1.5 ml microfuge tube and incubated with rat-anti-mouse CD31 (Mec13.3; BD Biosciences) coated with sheep anti-rat magnetic beads, and were gently rocked for 1 h at 4°C. Using a Dynal magnetic tube holder, cells not bound to magnetic beads were collected and washed in DMEM containing 10% FBS. Cells were plated in growth medium in a single well of a 24 well plate coated with human fibronectin (2 μg/ml in serum-free DMEM; BD Biosciences, Bedford, MA), and incubated at 33°C with 5% CO2. The cells bound to magnetic beads are generally used to remove retinal EC as we described \[[@pone.0231752.ref058]\]. Retinal AC were grown in DMEM containing 10% FBS, 2 mM L-glutamine, 2 mM sodium pyruvate, 20 mM HEPES, 1% nonessential amino acids, 100 μg/ml streptomycin, 100 U/ml penicillin, freshly added heparin at 55 U/ml (Sigma, St. Louis, MO), endothelial growth supplement 100 μg/ml (Sigma), and the murine recombinant interferon-γ (R&D, Minneapolis, MN) at 44 U/ml. Cells were maintained at 33°C with 5% CO2. Cells were progressively passed to larger plates, maintained, and propagated in 1% gelatin-coated 60 mm dishes. For all experiments, cells were used at 70--80% confluence unless stated otherwise.

RNA purification {#sec008}
----------------

Total RNA from Cyp1b1+/+ and Cyp1b1-/- retinal AC was purified using RNeasy Mini kit according to manufacturer's protocol with the DNAse treatment step to eliminate traces of genomic DNA (Qiagen, Germantown, MD). The quality and quantity of the total RNA were measured using an Agilent Model 2100 Bioanalyzer, and samples showing a RIN \>8 were selected for further analysis. Samples were stored in RNase-free water and kept at -80°C until further processing.

RNA sequencing {#sec009}
--------------

Eight samples of purified RNA (4 from *Cyp1b1*+/+ retinal AC and 4 from *Cyp1b1* -/- retinal AC) were subsequently subjected to a double round of poly-A mRNA purification, fragmented, and primed for cDNA library synthesis using the TruSeq RNA sample preparation kit (RS-122-9004). All procedures were carried out according to the manufacturer's instructions (Illumina, San Diego, CA). Following validation (Agilent 2100 Bioanalyzer, DNA 1000) and normalization, samples were clustered (TruSeq pairedend cluster kit v3-cBot-HS, PE-401-3001) followed by paired-end sequencing (100 bp; TruSeq SBS kit v3-HS 200 cycles, FC-401-3001) on a HiSeq2500. The following quality control statistics were used to evaluate the technical quality of the experiments; (1) combined per cycle base quality, (2) per cycle base frequencies, (3) per cycle average base quality, (4) relative 3k-mer diversity, (5) Phred quality distribution, (6) mean quality distribution, (7) read length distribution and (8) read occurrence distribution using the trimming software skewer \[[@pone.0231752.ref059]\]. Low-abundance genes with a read count below a threshold of 1.0 in two or more samples were excluded. To compare gene expression between Cyp1b1+/+AC and Cyp1b1-/-AC, samples were normalized by trimmed mean of M-values (TMM) using Edge R (version 2.5 of Bioconductor) software \[[@pone.0231752.ref016]\]. After the inspection of preliminary data, transcript reads were aligned to the preassembled selected reference genome sequence using STAR (Spliced Transcripts Alignment to a Reference) using the default settings \[[@pone.0231752.ref014]\]. Transcript abundance were performed by using RSEM (RNASeq by Expectation Maximization) \[[@pone.0231752.ref015]\]. Subsequently, differential analysis of significant changes in gene expression was performed with a glm using the edgeR package \[[@pone.0231752.ref017]\] in the different genotype pairs (e.g. *Cyp1b1*+/+ vs. *Cyp1b1* -/-). All sequence data have been deposited in the Gene Expression Omnibus with accession number GSE145103.

Quantitative RT-PCR {#sec010}
-------------------

Total RNA from retinal AC was extracted using mirVana PARIS kit (Invitrogen). The cDNA synthesis was performed from 1 μg of total RNA using Sprint RT Complete-Double PrePrimed kit (Clontech, Mountain View, CA). One μl of each cDNA (dilution 1∶10) was used as template in qPCR assays, performed in triplicate of three biological replicates on Mastercycler Realplex (Eppendorf) using the SYBR-Green qPCR Premix (Clontech). Amplification parameters were as follows: 95°C for 2 min; 40 cycles of amplification (95°C for 15 sec, 60°C for 40 sec); dissociation curve step (95°C for 15 sec, 60°C for 15 sec, 95°C for 15 sec). Standard curves were generated from known quantities for each of the target gene of linearized plasmid DNA. Ten times dilution series were used for each known target, which were amplified using SYBR-Green qPCR. The linear regression line for ng of DNA was determined from relative fluorescent units (RFU) at a threshold fluorescence value (Ct) to quantify gene targets from cell extracts by comparing the RFU at the Ct to the standard curve, normalized by the simultaneous amplification of RpL13a, a housekeeping gene. All primer sequence used are listed in [Table 4](#pone.0231752.t004){ref-type="table"}.

10.1371/journal.pone.0231752.t004

###### Primers to validate differentially express genes.

![](pone.0231752.t004){#pone.0231752.t004g}

  Gene          Amplicon size (bp)   primer   Primer Sequence (5\'-\>3\')   Length   Gene accession
  ------------- -------------------- -------- ----------------------------- -------- ----------------
  **Cxcl12**    116                  F        `ctgtgcccttcagattgttg`        20       NM_001012477.2
                                     R        `ctctgcgccccttgttta`          18       
  **Cxcl11**    93                   F        `tgctgagatgaacaggaaggt`       21       NM_019494.1
                                     R        `cgcccctgtttgaacataag`        20       
  **Col1a2**    69                   F        `ctggtgcacagggtgtga`          18       NM_007743.3
                                     R        `ctcctgcttgacctggagtt`        20       
  **Arnt2**     104                  F        `tgcacttcggaaaactccat`        20       NM_007488.3
                                     R        `cgagagcccatacacatgc`         19       
  **Fgf7**      78                   F        `ttactccatagttctgcaaccagt`    24       NM_008008.4
                                     R        `tgttgcccttcccttcataa`        20       
  **Mmp2**      75                   F        `gggcttctgtcctgacca`          18       NM_008610.3
                                     R        `aagttcttggtgtaggtgtagatcg`   25       
  **Bmp8b**     70                   F        `ctgtatgaactccaccaaccac`      22       NM_028189.3
                                     R        `ggggatgatatctggcttca`        20       
  **Cdh3**      75                   F        `aggcccagctaacacatgac`        20       NM_001037809.5
                                     R        `acaaggccacggtgtctc`          18       
  **Cdh4**      60                   F        `ttcctggctgctgacaatg`         19       NM_009867.3
                                     R        `gtagatctgcagggtcccagt`       21       
  **Gdf5**      73                   F        `tttattgacaaagggcaagatg`      22       NM_008109.3
                                     R        `aggcactgatgtcaaacacg`        20       
  **Cd80**      127                  F        `ttcgtctttcacaagtgtcttca`     23       NM_009855.2
                                     R        `tgccagtagattcggtcttca`       21       
  **Cldn1**     92                   F        `actccttgctgaatctgaacagt`     23       NM_016674.4
                                     R        `ggacacaaagattgcgatcag`       21       
  **Lefty1**    92                   F        `actcagtatgtggccctgcta`       21       NM_010094.4
                                     R        `aacctgcctgccacctct`          18       
  **Cysltr1**   95                   F        `aaggtgctgaggtaccagatagag`    24       NM_021476.5
                                     R        `aatcacagcccttgagaagc`        20       
  **Drd4**      137                  F        `cccaccaactacttcatcgtg`       21       NM_007878
                                     R        `gccatgagcgtgtcacag`          18       
  **Aldh1a7**   85                   F        `gtttgcagatgccgacttg`         19       NM_011921.2
                                     R        `cgctgcaacacaaatctgac`        20       
  **Cbr2**      109                  F        `gcccatgtcacctttcctaa`        20       NM_007621.2
                                     R        `ttacccggatcttgtgtgg`         19       
  **B3gnt3**    115                  F        `gcaaatacaaccgactgctg`        20       NM_028189.3
                                     R        `cactccaggaaaaggacctg`        20       
  **Cbr3**      60                   F        `aacgttagcgggagagatga`        20       NM_173047.3
                                     R        `cccttgatgtgggaaagaatc`       21       
  **Ldhb**      86                   F        `gtagtgggcgttggacaagt`        20       NM_001316322.1
                                     R        `acatccaccagggcaagtt`         19       
  **Gatm**      103                  F        `ggtgcactacatcggctctc`        20       NM_025961.5
                                     R        `acaggaatttcgggaggaa`         19       
  **Cacna1d**   60                   F        `gaagctgcttgaccaagttgt`       21       NM_001302637.1
                                     R        `aacttccccacggttacctc`        20       
  **Ccl7**      91                   F        `ttctgtgcctgctgctcata`        20       NM_013654.3
                                     R        `ttgacatagcagcatgtggat`       21       
  **MAPK13**    63                   F        `caggctggccttgagtctt`         19       NM_011950.2
                                     R        `ccagggctacacagtaagatcc`      22       
  **Adcy7**                          F        `gagccttccagacgtccat`         19       NM_007406.2
                70                   R        `aggaggataacggcattgg`         19       

Biological interaction network and KEGG pathway enrichment analysis {#sec011}
-------------------------------------------------------------------

Pathway Enrichment Analysis was performed with WEBGESTALT web analysis software (<http://bioinfo.vanderbilt.edu/wg2/>) by mapping significantly changed genes to corresponding KEGG enrichment pathways, Gene Ontology enrichment and conducting a hypergeometric statistical test with significant level \<0.05 after multiple testing correction \[[@pone.0231752.ref060]--[@pone.0231752.ref062]\]. Significance for pathway level enrichment was defined as having an enrichment score False Discovery Rate (FDR) corrected p-value \< 0.05.

Statistical analysis {#sec012}
--------------------

RNA-seq data were analyzed and gene expressions were normalized by the method of trimmed mean of M-values (TMM) and glm using the edgeR package, respectively. This yielded a total of 13,575 genes. KEGG pathway enrichment analysis cut-off criteria of FDR\<0.05 with a \|FC\|\>2 was apply. RT-PCR data were analyzed with student\'s unpaired t-test (2-tailed) or one-way ANOVA with post-Bonferroni's test for multiple comparisons. P≤ 0.05 was considered significant. Data are presented as Mean ± SEM from cells with n≥ 6 (as indicated in figure legends). All data analysis was done in GraphPad Prism or Microsoft Excel.
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